Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maravai LifeSciences Holdings's quarterly Beginning Cash Position
declined
from Sep. 2025 (MXN4,951 Mil) to Dec. 2025 (MXN4,386 Mil) and
declined
from Dec. 2025 (MXN4,386 Mil) to Mar. 2026 (MXN3,911 Mil).
Maravai LifeSciences Holdings's annual Beginning Cash Position
increased
from Dec. 2023 (MXN10,730 Mil) to Dec. 2024 (MXN11,991 Mil) but then
declined
from Dec. 2024 (MXN11,991 Mil) to Dec. 2025 (MXN5,805 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maravai LifeSciences Holdings Beginning Cash Position Chart
What does a Beginning Cash Position of MXN3,911 Mil mean?
Maravai LifeSciences Holdings (MEX:MRVI) has a Beginning Cash Position of MXN3,911 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Maravai LifeSciences Holdings and its competitors.
Is Maravai LifeSciences Holdings' Beginning Cash Position too high?
Maravai LifeSciences Holdings' current Beginning Cash Position is MXN3,911 Mil. Overall, Maravai LifeSciences Holdings has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' Beginning Cash Position compare to LBRX and AVTX?
Maravai LifeSciences Holdings' Beginning Cash Position of MXN3,911 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Maravai LifeSciences Holdings and its competitors. Maravai LifeSciences Holdings's current Beginning Cash Position is MXN3,911 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Maravai LifeSciences Holdings (MEX:MRVI) has a current Beginning Cash Position of MXN3,911 Mil. The stock's GF Value™ is MXN49.59, compared to a current price of MXN85.00 — trading 71.4% above its estimated fair value. The current Beginning Cash Position is MXN3,911 Mil. Maravai LifeSciences Holdings' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MEX:MRVI), the current Beginning Cash Position is MXN3,911 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MEX:MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of MXN85.00 is trading 71.4% above its estimated GF Value™ of MXN49.59.
Key valuation signals for MEX:MRVI:
Beginning Cash Position: MXN3,911 Mil
GF Value™: MXN49.59 vs. price of MXN85.00 (71.4% above fair value)
No single metric tells the full story. See the MEX:MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
60GF Score
Get the complete analysis for MEX:MRVI
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MRVI has been successfully added to your 
